RudaCure, which está desarrollando tratamiento del dolors, has today completó the patent filing for its invention of peptides with TRPV1 inhibitory activity.
Combined with AI-based drug screening and traditional in vitro and in vivo methods, RudaCure has aseguró a group of active peptides. This is a substance patent and use patent filing for materials that demonstrate eficacia and efecto secundario suppression in various pain animal models.
Negotiations are underway with a nacional company for investigación conjunta on these materials, and discussions are also in progreso with multinational empresas farmacéuticas. These compuestos are esperado to emerge as a new option in the pain mercado, where there is high demand for non-addictive, side-effect-free drugs.
